FDA OKs iCAD's Second Look 200 CAD technology
The FDA has cleared iCAD Inc.'s computer-aided detection (CAD) imaging technology, Second Look 200, for early detection of breast cancer with enhanced cancer detection software.
iCAD says the new combination of Second Look 200 with iCAD's Version 6.0 cancer detection software represents "both the most sensitive cancer detection solution available and the least expensive."
The Second Look 200 is designed to make CAD accessible to smaller breast care centers. iCAD says that the technology can analyze as many as 15 cases per day, is fully automated, fits on a counter top and is priced below $70,000. Version 6.0 detection software offers up to 94 percent sensitivity to all breast cancers.
iCAD adds that the Second Look 200 system also will be made available on a fee-per-procedure basis the company calls ClickCAD.
iCAD says the new combination of Second Look 200 with iCAD's Version 6.0 cancer detection software represents "both the most sensitive cancer detection solution available and the least expensive."
The Second Look 200 is designed to make CAD accessible to smaller breast care centers. iCAD says that the technology can analyze as many as 15 cases per day, is fully automated, fits on a counter top and is priced below $70,000. Version 6.0 detection software offers up to 94 percent sensitivity to all breast cancers.
iCAD adds that the Second Look 200 system also will be made available on a fee-per-procedure basis the company calls ClickCAD.